SinoPex's shares rose by over 13% during trading after the company announced it received approval from the Ministry of Food and Drug Safety for its domestically developed artificial kidney.
As of 2:20 PM on August 11, SinoPex's stock was trading at 4,660 won, up 555 won (13.52%) from the previous trading day, according to the Korea Exchange.
The company confirmed it had obtained formal product approval (No. 26-478) for its artificial kidney (HD), marking a significant milestone as the first of its kind developed in South Korea.
With this approval, SinoPex plans to accelerate the localization of hemodialysis medical devices. The company has already launched blood filters and water purifiers for artificial kidneys and is now preparing for mass production of the artificial kidney.
“This product approval for the artificial kidney is a starting point for establishing medical sovereignty in the domestic hemodialysis device sector, which has relied on imports,” said Kang Chang-ho, head of SinoPex's artificial kidney sales division. “We will prepare for the mass production of the artificial kidney alongside the blood filters and water purifiers already on the market.”
SinoPex is a KOSDAQ-listed advanced materials and components company specializing in flexible printed circuit boards (FPCB) and nano-membrane filters. The company is expanding its business while promoting the localization of hemodialysis medical devices.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.